专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20230125269A1 ADENOMYOSIS ASSOCIATED INFERTILITY AND HDAC INHIBITORS 有权
公开(公告)号：US20230125269A1
公开(公告)日：2023-04-27
申请号：US17998076
申请日：2021-04-13
申请人： NADEZHDA REPRODUCTIVE SCIENCE OOD
发明人： Gueorgui STAMENOV , Mariyana ENEVA
IPC分类号： A61K31/19 , A61P15/00
摘要： The present invention relates to new uses and methods of treatment. More specifically, the invention relates to new uses of histone deacetylase inhibitors (HDACI) such as valproic acid (VPA), for enhancing in vitro fertilization (IVF) in patients suffering with adenomyosis associated infertility.

2. 发明申请

US20230119628A1 KETONE ESTER AS A THERAPEUTIC TREATMENT OF COVID -19 AND RELATED VIRAL INFECTIONS 有权
公开(公告)号：US20230119628A1
公开(公告)日：2023-04-20
申请号：US17907470
申请日：2021-03-26
申请人： KETONEAID, INC.
发明人： Frank Borges LLOSA
IPC分类号： A61K31/22 , A61K31/375 , A61K31/23 , A61K31/706 , A61K31/047 , A61K31/19 , A61P31/14
摘要： Ketone bodies can be used to treat the human body from viral infections, and will overcome the cytokine storm, which leads to acute lung injury/acute respiratory distress syndrome. Based on this discovery, methods of treating humans from a viral infection like Covid-19 are disclosed which includes a therapeutically effective amount of an exogenous ketones including, but not limited to, ketone monoester (R)-3-hydroxybutyl (R)-3-hydroxybutanoate.

3. 发明申请

US20230112834A1 PARENTERAL FORMULATIONS OF TREPROSTINIL 有权
公开(公告)号：US20230112834A1
公开(公告)日：2023-04-13
申请号：US17900080
申请日：2022-08-31
申请人： United Therapeutics Corporation
发明人： Michael WADE
IPC分类号： A61K31/192 , A61K31/557 , A61K31/191 , A61K31/201 , A61K31/19 , A61K31/57
摘要： The present invention describes novel methods for using Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of ischemic lesions, such as digital ulcers, in subjects with scleroderma (including systemic sclerosis), Buerger's disease, Raynaud's disease, Raynaud's phenomenon and/or other conditions that cause such lesions. The invention also relates to kits for treatment and/or prevention of ischemic lesions, comprising an effective amount of Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof.

4. 发明申请

US20230102533A1 STARCH PROPIONATE USED AS A FOOD ADDITIVE AND/OR DIETARY SUPPLEMENT FOR PREVENTION OF OVERWEIGHT AND OBESITY 有权
公开(公告)号：US20230102533A1
公开(公告)日：2023-03-30
申请号：US17801199
申请日：2021-02-13
申请人： Ole Abilgaard , Theis Wilbek
发明人： Ole Abilgaard , Theis Wilbek
IPC分类号： A61K31/19 , A23L33/12 , A61K47/26
摘要： Starch propionate for humans is provided for weight loss and prevention of overweight and obesity. Starch propionate functions as a platform for delivery of propionic acid in the colon. It passes un-degraded to the colon, where propionic acid is released. Propionic acid in the colon stimulates the intestinal membrane to release appetite suppressing hormones GLP-1,(GLP-2) and PPY that reduces calorie intake and inhibits the production of fat in the liver and fat-tissue. Increased propionic acid in the blood inhibits fat production in the liver and fat-tissue. It also promotes the development of the gastrointestinal tract. Starch propionate can be used to reduce the appetite and calorie intake in humans.

5. 发明申请

US20230096528A1 Pharmaceutical Composition for Treatment or Prevention of Multiple Inflammatory disorders 有权
公开(公告)号：US20230096528A1
公开(公告)日：2023-03-30
申请号：US17845399
申请日：2022-06-21
申请人： AARDVARK THERAPEUTICS, INC.
发明人： Tien-Li LEE , Zhenhuan ZHENG , Andreas NIETHAMMER , Anjuli TIMMER
IPC分类号： A61K31/14 , A61K31/19 , A61K9/00 , A61P3/04
摘要： There is disclosed a method for treatment, prevention, and/or slowing of progression for various chronic inflammatory disorder groups including (1) type 2 diabetes group (metabolic syndrome (MET), obesity, hyperglycemia); (2) ARDS (acute respiratory distress syndrome); (3) chronic autoimmune inflammatory disorders (rheumatoid arthritis (RA), lupus, and psoriasis); (4) inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis; (5) metabolome-mediated diseases (atherosclerosis, hypertension, and congestive heart failure); and (6) hyperphagia disorders such as Prader-Willi Syndrome and other monogenic and syndromic obesity disorders including leptin pathway deficiencies, each comprising administering orally a pharmaceutical composition comprising a denatonium salt. The present disclosure is based on readouts from a series of studies tracking clusters of biomarkers levels to track mediators of inflammatory disorders and mediators of gut-signaling hormones in response to orally administered denatonium salts. There is further disclosed a pharmaceutical composition for treatment and prevention of various inflammatory conditions that can be tracked by pro-inflammatory biomarkers, comprising administering a pharmaceutical composition comprising a denatonium salt. Preferably, the pharmaceutical composition for daily oral administration comprises a denatonium salt delivering a daily total dose of from about 20 mg to about 5000 mg to a human adult BID. Preferably, the denatonium salt is selected from the group consisting of denatonium acetate, denatonium citrate, denatonium maleate and denatonium tartrate.

6. 发明申请

US20230091378A1 TRANSDERMAL ABSORPTION PREPARATION 有权
公开(公告)号：US20230091378A1
公开(公告)日：2023-03-23
申请号：US17904577
申请日：2021-02-18
申请人： Sumitomo Pharma Co., Ltd.
发明人： Eri ICHIBAYASHI , Masayasu TANAKA , Yuki IKEDA , Tomohito TAKITA , Kei TAMURA , Tetsuya NAKAMURA , Kaiji FUJIWARA
IPC分类号： A61K9/70 , A61K31/19 , A61K31/496 , A61K31/506 , A61K47/02 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/18 , A61K47/22
摘要： The present invention relates to a transdermal absorption preparation that can maintain a blood concentration sufficient to exert the efficacy of tandospirone, and also shows good storage stability against heat, humidity, and light. According to the present invention, a transdermal absorption preparation containing tandospirone or a pharmaceutically acceptable salt thereof, and levulinic acid, which is superior in the skin permeability of tandospirone or a pharmaceutically acceptable salt thereof in the preparation, and shows good preservation stability against heat and light can be provided.

7. 发明申请

US20230081059A1 METHOD OF TREATMENT AND PREVENTION OF BACTERIAL VAGINOSIS 有权
公开(公告)号：US20230081059A1
公开(公告)日：2023-03-16
申请号：US17821157
申请日：2022-08-19
申请人： EVOFEM, INC.
发明人： David R. FRIEND
IPC分类号： A61K31/19 , A61K9/00 , A61P15/02 , A61K47/12 , A61K47/38
摘要： Described herein are methods of reducing the risk of recurrence of bacterial vaginosis by intravaginal administration of compositions comprising L-lactic acid, polymer thickener, and preservative.

8. 发明申请

US20230075547A1 KETONE BODIES AND KETONE BODY ESTERS AS BLOOD LIPID LOWERING AGENTS 有权
公开(公告)号：US20230075547A1
公开(公告)日：2023-03-09
申请号：US17728600
申请日：2022-04-25
申请人： OXFORD UNIVERSITY INNOVATION LIMITED , Government of the USA, as represented by the Secretary, Department of Health and Human Services
发明人： Kieran Clarke , Richard Lewis Veech
IPC分类号： A61K31/22 , A61P3/10 , A61P3/06 , A61K31/047 , A61K31/19 , A61K31/365 , A61K45/06 , A61K9/00
摘要： The subject disclosure provides compositions for reducing serum cholesterol and/or triglyceride levels in subjects. These compositions can comprise racemic β-hydroxybutyrate or D-β-hydroxybutyrate, optionally in the acid form, physiologically compatible salts of racemic β-hydroxybutyrate or D-β-hydroxybutyrate, esters of D-β-hydroxybutyrate, oligomers of D-β-hydroxybutyrate containing from 2 to 20 or more monomeric units in either linear or cyclic form, racemic 1,3 butandiol or R-1,3 butandiol alone and can be, optionally, administered in conjunction with a low fat diet to a subject. Alternatively, compositions comprising racemic β-hydroxybutyrate or D-β-hydroxybutyrate, optionally in the acid form, physiologically compatible salts of racemic β-hydroxybutyrate or D-β-hydroxybutyrate, esters of D-β-hydroxybutyrate, oligomers of D-β-hydroxybutyrate containing from 2 to 20 or more monomeric units in either linear or cyclic form, racemic 1,3 butandiol, R-1,3 butandiol or combinations thereof can be formulated as nutritional supplements (also referred to as nutritional compositions) or incorporated into therapeutic compositions containing a) anti-hypertensive agents; b) anti-inflammatory agents; c) glucose lowering agents; or d) anti-lipemic agents) which are administered to a subject, optionally in combination with a low fat diet, in order to cause a reduction or lowering of: serum cholesterol levels; triglyceride levels; serum glucose levels, serum homocysteine levels, inflammatory proteins (e.g., C reactive protein) and/or hypertension in treated subjects. Alternatively, compositions disclosed herein can be administered alone, or in combination with other therapeutic agents to prevent or reverse vascular disease.

9. 发明申请

US20230069590A1 CONCENTRATED SODIUM VALPROATE FOR RAPID DELIVERY 有权
公开(公告)号：US20230069590A1
公开(公告)日：2023-03-02
申请号：US17792856
申请日：2021-01-13
申请人： The Regents of the University of Michigan
发明人： Manjunath P. Pai , Ben Biesterveld , Hasan Alam
IPC分类号： A61K31/19 , A61K9/00 , A61P43/00
摘要： Provided herein are pharmaceutical compositions comprising concentrated valproic acid (e.g., >200 mg/mL) for rapid delivery of high doses (e.g., 100-200 mg/kg) of valproic acid to subjects (e.g., intraosseous, intravenous, etc.), and methods of treating emergency injuries and conditions therewith.

10. 发明申请

US20230061319A1 METHODS OF TREATING TUMORS 有权
公开(公告)号：US20230061319A1
公开(公告)日：2023-03-02
申请号：US17758558
申请日：2021-01-08
申请人： CoImmune, Inc.
发明人： Joseph HORVATINOVICH , Mark DEBENEDETTE , Charles NICOLETTE , Irina TCHEREPANOVA
IPC分类号： A61K39/00 , A61K31/436 , A61K39/395 , A61K31/167 , A61K31/573 , A61K31/664 , A61K31/519 , A61K31/5377 , A61K31/52 , A61K31/517 , A61K31/58 , A61K31/55 , A61K31/19 , A61K31/515 , A61K31/4166 , A61K31/454 , A61K31/4706 , A61K31/439 , A61K31/505 , A61K31/65 , A61K31/7056 , A61P35/00
摘要： The present disclosure provides methods of treating a tumor (e.g., renal cell cancer) by administering an immunotherapy comprising dendritic cells loaded with RNA encoding a tumor antigen and a pharmaceutical which can decrease circulating IgG levels, block IgG-mediated activation of CD16+ T cells, decrease the concentration and/or function of B cells, reduce the frequency of CD38+ TGF-β+ B cells, decrease B cell secretion of TGF-β, and/or sustain the frequency of CD25+CD28+ CD4 and/or CD8 T cells.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式